<DOC>
	<DOCNO>NCT00332332</DOCNO>
	<brief_summary>The purpose study evaluate use etanercept ( Enbrel® ) treatment psoriasis patient period 1 year .</brief_summary>
	<brief_title>Canadian Assessment Patient Outcomes Effectiveness Etanercept ( Enbrel ) Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>18 year age old baseline Moderate severe plaque psoriasis baseline rating moderate , mark severe Physician Global Assessment ( score 3 , 4 5 ) Able start Enbrel ( Etanercept ) therapy per approve product monograph Exclusion Criteria Active infection initiation Enbrel therapy . Evidence skin condition ( i.e . eczema ) psoriasis would interfere evaluation effect study medication psoriasis . Psoralen plus ultraviolet A radiation ( PUVA ) within 4 week ultraviolet light B ( UVB ) therapy within 2 week study drug initiation . Oral retinoids , cyclosporine , methotrexate , systemic antipsoriasis therapy within 4 week efalizumab ( Raptiva® ) within 8 week study drug initiation study period . Topical Vitamin A D analog preparation , anthralin within 2 week study drug initiation study period . Have receive Remicade® ( infliximab ) , Humira® ( adalimumab ) Amevive® ( alefacept ) within 3 month initiation study medication study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Phase IV</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Inflammation</keyword>
</DOC>